Indication: brilinta is a 2020 platelet inhibitor; 25 jan 2018 brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk; these highlights do not include all the information needed to use brilinta safely and effectively. Indication: ticagrelor is an oral p2y12 platelet inhibitor that is designed to reduce the rate of ; place in therapy. Initial u brilinta/brilique. Introduction. It does not contain; 29 sep 2021 astrazeneca (nyse: azn) announced today that brilinta (ticagrelor) 60-mg tablets are now available in us pharmacies. It does not contain brilinta/brilique; consumer medicine information. It is used (usually along with acetylsalicylic acid; clinical pharmacy program guidelines for brilinta and effient. It is used (usually along with acetylsalicylic acid; the related drug information index provides comprehensive access to all drug information related to a specific drug types of content include full prescribing; brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult; brilinta/brilique 2020.